The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

"Novartis’ mAb could become first Sjögren’s disease drug after Phase III success" was originally created and published by ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

Patients with Sjögren syndrome have an increased risk for non-Hodgkin lymphoma. It is estimated that approximately 10% of patients with significant dry eye disease have Sjögren syndrome.

Considering that IgG4-related syndrome also affects the parotid glands frequently, this overlap in symptoms further supports biopsy as a method to ensure the correct diagnosis of Sjögren's ...